Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer

BACKGROUND: Evidence of the efficacy of immune checkpoint inhibitors (ICIs) plus antiangiogenic drugs in previously treated patients with advanced non-small-cell lung cancer (NSCLC) is still insufficient, so we investigated the safety and efficacy of nivolumab plus recombinant human (rh)-endostatin i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Weize, Pei, Xiaofeng, Zhao, Wenhua, Cong, Yunyan, Wei, Yajun, Li, Ting, Zhang, Hongyu, Lin, Zhong, Saito, Yuichi, Kim, Jae Jun, Liang, Zibin, Zhong, Beilong, Wang, Zhihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902090/
https://www.ncbi.nlm.nih.gov/pubmed/35280309
http://dx.doi.org/10.21037/tlcr-22-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902090/
https://www.ncbi.nlm.nih.gov/pubmed/35280309
http://dx.doi.org/10.21037/tlcr-22-49

Ejemplares similares